An oncolytic vaccinia virus encoding CD47 nanobody potentiates antitumor immunity in multiple myeloma - PubMed
5 hours ago
- #immunotherapy
- #multiple myeloma
- #oncolytic virus
- An oncolytic vaccinia virus encoding CD47 nanobody (OVV-αCD47nb) was engineered to target multiple myeloma (MM).
- OVV-αCD47nb combines direct oncolysis with localized CD47-SIRPα axis blockade to enhance macrophage phagocytosis of tumor cells.
- In murine MM models, OVV-αCD47nb suppressed tumor growth, extended survival, and induced durable responses without hematologic toxicity.
- The virus remodeled the tumor microenvironment by polarizing macrophages to M1-like phenotypes and enhancing CD8+ T cell infiltration and function.
- Transcriptomics showed enriched pro-inflammatory and phagocytic pathways with downregulated autophagy genes.
- OVV-αCD47nb synergized with bortezomib to overcome resistance and improve tumor control over monotherapies.
- This strategy integrates oncolysis, immune reprogramming, and chemosensitization for CD47-expressing malignancies.